These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1212241)

  • 1. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis.
    Salen G; Meriwether TW; Nicolau G
    Biochem Med; 1975 Sep; 14(1):57-74. PubMed ID: 1212241
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism.
    Salen G
    Ann Intern Med; 1971 Dec; 75(6):843-51. PubMed ID: 5134895
    [No Abstract]   [Full Text] [Related]  

  • 3. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
    Salen G; Shefer S; Tint GS
    Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cerebrotendinous xanthomatosis].
    Berginer VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(4):13-22. PubMed ID: 1333699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
    Kuriyama M; Fujiyama J; Kasama T; Osame M
    J Lipid Res; 1991 Feb; 32(2):223-9. PubMed ID: 2066659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
    Batta AK; Salen G; Tint GS
    Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric disorders in patients with cerebrotendinous xanthomatosis.
    Berginer VM; Foster NL; Sadowsky M; Townsend JA; Siegel GJ; Salen G
    Am J Psychiatry; 1988 Mar; 145(3):354-7. PubMed ID: 3344851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
    Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
    Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis.
    Salen G; Batta AK; Tint GS; Shefer S
    Metabolism; 1994 Aug; 43(8):1018-22. PubMed ID: 8052141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.
    Koopman BJ; Wolthers BG; van der Molen JC; van der Slik W; Waterreus RJ; van Spreeken A
    J Inherit Metab Dis; 1988; 11(1):56-75. PubMed ID: 3128689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26.
    Salen G; Shefer S; Tint GS; Nicolau G; Dayal B; Batta AK
    J Clin Invest; 1985 Aug; 76(2):744-51. PubMed ID: 4031069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and enterohepatic circulation of bile salts.
    Hanson RF; Pries JM
    Gastroenterology; 1977 Sep; 73(3):611-8. PubMed ID: 330305
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effects of cholestanol and cholesterol on hepatic sterol and bile acid metabolism in the rat.
    Shefer S; Hauser S; Salen G; Zaki FG; Bullock J; Salgado E; Shevitz J
    J Clin Invest; 1984 Nov; 74(5):1773-81. PubMed ID: 6501569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.
    Salen G; Grundy SM
    J Clin Invest; 1973 Nov; 52(11):2822-35. PubMed ID: 4355999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel pathway for biosynthesis of cholestanol with 7 alpha-hydroxylated C27-steroids as intermediates, and its importance for the accumulation of cholestanol in cerebrotendinous xanthomatosis.
    Skrede S; Björkhem I; Buchmann MS; Hopen G; Fausa O
    J Clin Invest; 1985 Feb; 75(2):448-55. PubMed ID: 3919058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acid profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis.
    Kihira K; Shimazu K; Kuwabara M; Yoshii M; Takeuchi H; Nakano I; Ozawa S; Onuki M; Hatta Y; Hoshita T
    Steroids; 1986; 48(1-2):109-19. PubMed ID: 3660436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
    Salen G; Berginer V; Shore V; Horak I; Horak E; Tint GS; Shefer S
    N Engl J Med; 1987 May; 316(20):1233-8. PubMed ID: 3106810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of biliary ursodeoxycholic acid in guinea pig during early stages of cholestyramine feeding.
    Li JR; Dinh DM; Kottke BA
    Steroids; 1979; 34(6 Spec no):705-15. PubMed ID: 538776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
    Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
    Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosynthesis of 5 -cholestan-3 -ol in cerebrotendinous xanthomatosis.
    Salen G; Polito A
    J Clin Invest; 1972 Jan; 51(1):134-40. PubMed ID: 4550120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.